The development of effective cancer therapies is hindered by the heterogeneity of tumors and the lack of reliable methods for predicting drug response in specific patient populations. Traditional drug development and clinical trials often fail to account for individual genetic and molecular profiles, leading to suboptimal treatment outcomes.

Oncolines offers precision medicine services that leverage bioinformatics analysis, gene mutation profiling, and cell-based assays to optimize oncology and immunotherapy development. The company's services enable the identification of patient selection markers and the discovery of synergistic drug combinations. By profiling drug candidates against a large panel of human cancer cell lines, Oncolines facilitates the development of targeted therapies and accelerates access to effective treatments for specific patient populations. Their approach integrates cancer biology with big data analysis to provide insights into drug mechanisms and predictive biomarkers.

Compound profiling on a large panel of human cancer cell lines

Cell toxicity assays as an alternative readout for cancer cell panel profiling studies

Gene expression profiling to understand and combat drug resistance

Identification of patient selection markers for targeted therapies

Discovery of novel synergistic drug combinations

3D spheroid drug sensitivity testing

Analysis of drug resistance mechanisms

Target validation using Oncolines profiling and gene dependency screens

The primary customers are pharmaceutical and biotechnology companies involved in oncology and immunotherapy drug development, as well as researchers seeking to identify predictive biomarkers and optimize treatment strategies.